文献速递膀胱癌与上尿路尿路上皮癌肾癌与肾肿瘤

无症状镜下血尿评估中的诊断影像学:系统综述与Meta分析

Diagnostic Imaging in the Evaluation of Asymptomatic Microhematuria: Systematic Review and Meta-analysis.
PubMed 文献 · J Urol · 2023-03-08

本系统综述与Meta分析基于2020年AUA镜下血尿指南报告所收集的证据,纳入2010年1月至2019年12月发表的研究,评估CT尿路造影、肾脏超声和磁共振尿路造影在镜下血尿和肉眼血尿患者中诊断上尿路癌的诊断试验特征。共检索到20项研究,其中6项纳入定量分析。CT尿路造影 pooled 4项研究灵敏度94%(95%CI,84%-98%)、特异度99%(95%CI,97%-100%);超声2项研究灵敏度14%-96%、特异度99%-100%;磁共振尿路造影1项研究灵敏度83%、特异度86%。

要点

  • CT尿路造影 pooled 4项研究诊断肾细胞癌和上尿路癌的灵敏度94%、特异度99%。
  • 超声2项研究灵敏度范围14%-96%,特异度99%-100%。
  • 磁共振尿路造影1项研究灵敏度83%、特异度86%。

核心结论

  • 在每种影像学方法各自有限的数据集中,CT尿路造影似乎是诊断评估镜下血尿最敏感的影像学方法。
  • 未来需要研究评估指南推荐从CT尿路造影转向肾脏超声用于低危和中危镜下血尿患者所带来的临床和卫生系统财务影响。

研究设计与样本

  • 本研究为系统综述与Meta分析,遵循PRISMA指南,使用为2020年AUA镜下血尿指南报告收集的证据。
  • 检索范围包括2010年1月至2019年12月发表的、评估血尿诊断后影像学检查的研究。
  • 共检索到20项报告影像学方法与恶性及良性诊断患病率关系的研究,其中6项纳入定量分析。

主要发现

  • CT尿路造影 pooled 4项研究检测肾细胞癌和上尿路癌的灵敏度为94%(95%CI,84%-98%),特异度为99%(95%CI,97%-100%),证据确定性评级分别为极低和低。
  • 超声2项研究灵敏度范围为14%-96%(证据确定性低),特异度为99%-100%(证据确定性中等)。
  • 磁共振尿路造影1项研究灵敏度为83%、特异度为86%,证据确定性低。

关键数值与推荐

  • CT尿路造影 pooled 4项研究:灵敏度94%(95%CI,84%-98%),特异度99%(95%CI,97%-100%)。
  • 超声2项研究:灵敏度14%-96%,特异度99%-100%。
  • 磁共振尿路造影1项研究:灵敏度83%,特异度86%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 每种影像学方法各自的数据集有限。
  • 未来需要研究评估指南推荐从CT尿路造影转向肾脏超声用于低危和中危镜下血尿患者的临床和卫生系统财务影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Microhematuria is a highly prevalent condition with a low associated risk of urothelial and upper tract malignancy. The AUA Guidelines recently changed recommendations for imaging favoring renal ultrasound for low- and intermediate-risk patients with microhematuria. We summarize the diagnostic test characteristics of computed tomography urography, renal ultrasound, and magnetic resonance urography in comparison with surgical pathology for the diagnosis of upper urinary tract cancer in microhematuria and gross hematuria patients. MATERIALS AND METHODS: This study is a systematic review and meta-analysis using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines from evidence collected for the 2020 AUA Microhematuria Guidelines report, including studies assessing imaging following diagnosis of hematuria published from January 2010 through December 2019. RESULTS: The search identified 20 studies which reported the prevalence of malignant and benign diagnoses in relation to imaging modality, of which 6 were included in the quantitative analysis. For the detection of renal cell carcinoma and upper urinary tract carcinoma in patients with microhematuria and gross hematuria, computed tomography urography had a sensitivity of 94% (95% CI, 84%-98%) and a specificity of 99% (95%CI, 97%-100%) with a certainty of evidence rating of very low and low, respectively when 4 studies were pooled. In comparison, ultrasound demonstrated a sensitivity ranging from 14%-96% (low certainty of evidence) and a specificity of 99%-100% in 2 studies (moderate certainty of evidence), while magnetic resonance urography demonstrated a sensitivity of 83% and specificity of 86% in 1 study with a low certainty of evidence. CONCLUSIONS: In a limited data set for each individual imaging modality, computed tomography urography appears the most sensitive imaging modality for the diagnostic evaluation of microhematuria. Future studies will be needed to evaluate the clinical and health system financial impacts of the change in guideline recommendations from computed tomography urography to renal ultrasound in evaluating low- and intermediate-risk patients with microhematuria.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Taylor JI, Souter LH, Barocas DA, et al. Diagnostic Imaging in the Evaluation of Asymptomatic Microhematuria: Systematic Review and Meta-analysis. J Urol. 2023. PMID: 36883858. doi:10.1097/JU.0000000000003395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。